Metraipolis › archive › dc_96fec0e73dc0

Posttreatment squamous cell carcinoma antigen: A prognostic marker for patients with advanced cervical cancer treated with bevacizumab-paclitaxel-cisplatin… — Europe PMC PMID:40988228

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40988228
DOI
10.1097/md.0000000000044673
License (as archived)
solo-consultazione
Archived
2026-11-10T05:22:55.477Z
SHA-256 of the archived text
3ef430a0e07cfa7fda914ba18d94019eff0a845e47c6bae4a66296e8a6eb9f15
Stable URL of this page
https://metraipolis.com/documento/dc_96fec0e73dc0

How to cite

Posttreatment squamous cell carcinoma antigen: A prognostic marker for patients with advanced cervical cancer treated with bevacizumab-paclitaxel-cisplatin… — Europe PMC PMID:40988228 — Europe PMC (en), https://europepmc.org/article/MED/40988228 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_96fec0e73dc0 (Metraipolis archive dc_96fec0e73dc0, sha256 3ef430a0e07cfa7fda914ba18d94019eff0a845e47c6bae4a66296e8a6eb9f15)
BibTeX
@misc{dc96fec0e73dc0,
  title = {Posttreatment squamous cell carcinoma antigen: A prognostic marker for patients with advanced cervical cancer treated with bevacizumab-paclitaxel-cisplatin… — Europe PMC PMID:40988228},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40988228},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_96fec0e73dc0; sha256 3ef430a0e07cfa7fda914ba18d94019eff0a845e47c6bae4a66296e8a6eb9f15},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40988228. Agents can read the archived copy with the MCP tool read_document.